Education
About Us
Working with TipRanks
Follow Us
Bioventus (BVS)
NASDAQ:BVS
BVS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.81 - $14.38
Previous CloseN/A
Volume116.12K
Average Volume (3M)458.19K
Market Cap
$592.81M
Enterprise Value$831.80M
Total Cash (Recent Filing)$32.91M
Total Debt (Recent Filing)$341.24M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Nov 11, 2025EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.21
Shares Outstanding66,892,300
10 Day Avg. Volume258,608
30 Day Avg. Volume458,193
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.40
Enterprise Value/Revenue1.47
Enterprise Value/Gross Profit2.18
Enterprise Value/Ebitda9.85
Forecast
1Y Price Target
$14.67Price Target Upside114.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCash flow from operations materially increased 71% to nearly $26M, indicating strong financial performance.
Growth StrategyBioventus has set in place levers to drive both short and long-term growth and expects a back-half improvement in its growth rate.
Product InnovationBioventus's Ultrasonics platform in surgical solutions offers the potential to shift the standard of care in spinal surgery and bone cutting with enhanced precision and efficiency.
Bears Say
Market CompetitionBioventus is trading at an attractive valuation, at half the multiple of its small-cap MedTech peers, supporting the analyst's recommendation to maintain a BUY rating.
Valuation ConcernsBioventus's attractive valuation, trading at half the multiple of its small-cap MedTech peers, supports the analyst's recommendation to maintain a BUY rating.
Bioventus News
BVS FAQ
What was Bioventus’s price range in the past 12 months?
Bioventus lowest stock price was $5.81 and its highest was $14.38 in the past 12 months.
What is Bioventus’s market cap?
Bioventus’s market cap is $592.81M.
When is Bioventus’s upcoming earnings report date?
Bioventus’s upcoming earnings report date is Nov 11, 2025 which is in 54 days.
How were Bioventus’s earnings last quarter?
Bioventus released its earnings results on Aug 06, 2025. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.157 by $0.053.
Is Bioventus overvalued?
According to Wall Street analysts Bioventus’s price is currently Undervalued.
Does Bioventus pay dividends?
Bioventus does not currently pay dividends.
What is Bioventus’s EPS estimate?
Bioventus’s EPS estimate is 0.11.
How many shares outstanding does Bioventus have?
Bioventus has 66,892,300 shares outstanding.
What happened to Bioventus’s price movement after its last earnings report?
Bioventus reported an EPS of $0.21 in its last earnings report, beating expectations of $0.157. Following the earnings report the stock price went up 18.73%.
Which hedge fund is a major shareholder of Bioventus?
Currently, no hedge funds are holding shares in BVS
Bioventus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.67 (114.47% Upside)
$14.67 (114.47% Upside)
Blogger Sentiment
Bullish
BVS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 2.6%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.15%
12-Months-Change
Fundamentals
Return on Equity
-0.10%
Trailing 12-Months
Asset Growth
-10.78%
Trailing 12-Months
Company Description
Bioventus
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
BVS Company Deck
BVS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with strong financial results, strategic growth in key business areas, and significant opportunities from new product clearances. However, challenges from divestiture impacts, foreign exchange losses, and tariff headwinds were acknowledged.View all BVS earnings summariesBVS Stock 12 Month Forecast
Average Price Target
$14.67
▲(114.47% Upside)
Technical Analysis
Ownership Overview
31.90% Insiders
8.25% Mutual Funds
46.04% Other Institutional Investors
5.37% Public Companies and
Individual Investors